Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology

Because a correlation between tau pathology and the clinical symptoms of Alzheimer disease (AD) has been hypothesized, there is increasing interest in developing PET tracers that bind specifically to tau protein. The aim of this study was to evaluate tracer kinetic models for quantitative analysis and generation of parametric images for the novel tau ligand (S)-18F-THK5117. Methods: Nine subjects (5 with AD, 4 with mild cognitive impairment) received a 90-min dynamic (S)-18F-THK5117 PET scan. Arterial blood was sampled for measurement of blood radioactivity and metabolite analysis. Volume-of-interest (VOI)–based analysis was performed using plasma-input models; single-tissue and 2-tissue (2TCM) compartment models and plasma-input Logan and reference tissue models; and simplified reference tissue model (SRTM), reference Logan, and SUV ratio (SUVr). Cerebellum gray matter was used as the reference region. Voxel-level analysis was performed using basis function implementations of SRTM, reference Logan, and SUVr. Regionally averaged voxel values were compared with VOI-based values from the optimal reference tissue model, and simulations were made to assess accuracy and precision. In addition to 90 min, initial 40- and 60-min data were analyzed. Results: Plasma-input Logan distribution volume ratio (DVR)-1 values agreed well with 2TCM DVR-1 values (R2 = 0.99, slope = 0.96). SRTM binding potential (BPND) and reference Logan DVR-1 values were highly correlated with plasma-input Logan DVR-1 (R2 = 1.00, slope ≈ 1.00) whereas SUVr70–90-1 values correlated less well and overestimated binding. Agreement between parametric methods and SRTM was best for reference Logan (R2 = 0.99, slope = 1.03). SUVr70–90-1 values were almost 3 times higher than BPND values in white matter and 1.5 times higher in gray matter. Simulations showed poorer accuracy and precision for SUVr70–90-1 values than for the other reference methods. SRTM BPND and reference Logan DVR-1 values were not affected by a shorter scan duration of 60 min. Conclusion: SRTM BPND and reference Logan DVR-1 values were highly correlated with plasma-input Logan DVR-1 values. VOI-based data analyses indicated robust results for scan durations of 60 min. Reference Logan generated quantitative (S)-18F-THK5117 DVR-1 parametric images with the greatest accuracy and precision and with a much lower white-matter signal than seen with SUVr70–90-1 images.

[1]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[2]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[3]  Paul Edison,et al.  A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[5]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Anton Forsberg,et al.  The use of PIB-PET as a dual pathological and functional biomarker in AD. , 2012, Biochimica et biophysica acta.

[8]  Olaf B. Paulson,et al.  MR-based automatic delineation of volumes of interest in human brain PET images using probability maps , 2005, NeuroImage.

[9]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[10]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[11]  P. Vemuri,et al.  Brain β-amyloid load approaches a plateau , 2013, Neurology.

[12]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[13]  Kazuhiko Yanai,et al.  Tau PET Imaging in Alzheimer’s Disease , 2014, Current Neurology and Neuroscience Reports.

[14]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[16]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[17]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[18]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[19]  Christopher C Rowe,et al.  Tau imaging: early progress and future directions , 2015, The Lancet Neurology.

[20]  M. Hüll,et al.  Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.

[21]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[22]  H. Akaike A new look at the statistical model identification , 1974 .

[23]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[24]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.